<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cefotetan</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01330</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01330/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01330/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01330.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01330.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01330.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01330.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01330.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01330">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Cefotetanum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cefotan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Yamatetan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/cephalosporins">Cephalosporins</a></li></ul></td></tr><tr><th>CAS number</th><td>69712-56-7</td></tr><tr><th>Weight</th><td>Average: 575.619<br>Monoisotopic: 575.002143315</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>17</sub>N<sub>7</sub>O<sub>8</sub>S<sub>4</sub></td></tr><tr><th>InChI Key</th><td>SRZNHPXWXCNNDU-IXOPCIAXSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/b12-6-/t13?,15-,17+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(6R,7S)-7-{4-[carbamoyl(carboxy)methylidene]-1,3-dithietane-2-amido}-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Lactams</td></tr><tr><th>Subclass</th><td>Beta Lactams</td></tr><tr><th>Direct parent</th><td>Cephalosporins</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids and Derivatives; 1,3-Thiazines; Dicarboxylic Acids and Derivatives; Tetrazoles; Enones; Tertiary Carboxylic Acid Amides; Hemiaminals; Dithietanes; Primary Carboxylic Acid Amides; Polyols; Secondary Carboxylic Acid Amides; Azetidines; Tertiary Amines; Polyamines; Enamines; Carboxylic Acids; Enolates; Aminals; Acetals; Thioethers</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; meta-thiazine; dicarboxylic acid derivative; enone; tetrazole; azole; tertiary carboxylic acid amide; dithietane; tertiary amine; azetidine; polyol; secondary carboxylic acid amide; primary carboxylic acid amide; hemiaminal; carboxamide group; polyamine; ether; thioether; enamine; acetal; enolate; aminal; carboxylic acid derivative; carboxylic acid; alcohol; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moeity or a derivative thereof.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For prophylaxis and treatment of bacterial infections.</td></tr><tr><th>Pharmacodynamics</th><td>Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. </td></tr><tr><th>Mechanism of action</th><td>The bactericidal action of cefotetan results from inhibition of cell wall synthesis by binding and inhibiting the bacterial penicillin binding proteins which help in the cell wall biosynthesis.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>10.4 L [elderly patients (greater than 65 years) with normal renal function]</li>
	<li>10.3 L [healthy volunteers (aged 25 to 28 years)]</li>
</ul></td></tr><tr><th>Protein binding</th><td>Cefotetan is 88% plasma protein bound.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.</p></td></tr><tr><th>Route of elimination</th><td>No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.</td></tr><tr><th>Half life</th><td>In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged</td></tr><tr><th>Clearance</th><td><ul>
	<li>1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)]</li>
	<li>1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)]</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.9451</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9903</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.799</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7418</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8992</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7207</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9032</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8489</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8219</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8308</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6374</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7712
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9274
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9081
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.7915 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9933
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7103
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astrazeneca pharmaceuticals lp</li>
<li>App pharmaceuticals llc</li>
<li>B braun medical inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.bbraun.com">B. Braun Melsungen AG</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Intramuscular</td><td></td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The cephalosporin, cefotetan, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00479">Amikacin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The cephalosporin, cefotetan, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The cephalosporin, cefotetan, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00798">Gentamicin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01172">Kanamycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00994">Neomycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00955">Netilmicin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01032">Probenecid</a></td><td>Probenecid may increase the serum level of cefotetan.</td></tr><tr><td><a href="/drugs/DB01082">Streptomycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The cephalosporin, cefotetan, may increase the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol as it can cause a disulfiram effect.</li></ul></td></tr></tbody></table>